Inactive Instrument

Highlights JHL Biotech, Inc.

Equities

6540

KYG7863U1076

Highlights

Unlock all the news: Be the first to know and act before the market!

Bora Pharmaceutical Laboratories Inc. acquired CDMO Assets of JHL Biotech, Inc. for $100 million.	22-05-09	CI
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar	20-05-18	CI
JHL Biotech, Inc. Announces First Patient Randomized in the Phase Iii Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma	18-12-27	CI
JHL Biotech, Inc. Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer	18-10-15	CI
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer	18-08-09	CI
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar	18-07-09	CI
Jhl Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma	18-07-05	CI
JHL Biotech, Inc. announced that it has received $106 million in funding from a group of investors	18-05-14	CI
JHL Biotech, Inc. Announces European Authority, Bulgarian Drug Agency Approves Phase I Clinical Trial Application	18-02-22	CI
JHL Biotech, Inc.'s Board intends to launch an Equity Buyback.	18-02-05	CI
JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis	17-12-20	CI
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers	17-12-20	CI
JHL Biotech Inc Announces Its Clinical Trial Application for Use of JHL1101 in Phase 1 and Phase 3 Clinical Trials	17-04-04	CI
JHL Doses First Patient In JHL1101 Phase I European Trial	17-03-29	CI
Sanofi Enters into Strategic Biologics Alliance with JHL Biotech in China	16-12-05	CI
JHL Biotech, Inc. Enters into A Contract Manufacturing Agreement with BeiGene, Ltd	16-06-13	CI
JHL Biotech Opens Biopharmaceutical Manufacturing Facility in China	16-05-15	CI
JHL Biotech, Inc. Enters into a Contract Manufacturing Master Service Agreement with Affinita Biotech	16-02-29	CI
JHL Biotech, Inc. Receives Approval from European Authorities to Begin Biosimilar Clinical Trial	16-02-14	CI
BioLineRx and JHL Biotech to Collaborate on Type 1 Diabetes Antibody Treatment	14-01-08	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights JHL Biotech, Inc.

Equities

6540

KYG7863U1076

Highlights

Filters